The invention relates to systems and devices for closure of blood vessel punctures, and more particularly, the invention relates to systems and methods for facilitating hemostasis of blood vessel punctures with an absorbable sponge material.
A large number of diagnostic and interventional procedures involve the percutaneous introduction of instrumentation into a vein or artery. For example, coronary angioplasty, angiography, atherectomy, stenting of arteries, and many other procedures often involve accessing the vasculature through a catheter placed in the femoral artery or other blood vessel. Once the procedure is completed and the catheter or other instrumentation is removed, bleeding from the punctured artery must be controlled.
Traditionally, external pressure is applied to the skin entry site to stem bleeding from a puncture wound in a blood vessel. Pressure is continued until hemostasis has occurred at the puncture site. In some instances, pressure must be applied for a up to an hour or more during which time the patient is uncomfortably immobilized. In addition, a risk of hematoma exists since bleeding from the vessel may continue beneath the skin until sufficient clotting effects hemostasis. Further, external pressure to close the vascular puncture site works best when the vessel is close to the skin surface and may be unsuitable for patients with substantial amounts of subcutaneous adipose tissue since the skin surface may be a considerable distance from the vascular puncture site.
More recently, devices have been proposed to promote hemostasis directly at a site of a vascular puncture. One class of such puncture sealing devices features an intraluminal anchor which is placed within the blood vessel and seals against an inside surface of the vessel puncture. The intraluminal plug may be used in combination with a sealing material positioned on the outside of the blood vessel, such as collagen. Sealing devices of this type are disclosed in U.S. Pat. Nos. 4,852,568; 4,890,612; 5,021,059; and 5,061,274.
Another approach to subcutaneous blood vessel puncture closure involves the delivery of non-absorbable tissue adhesives, such cyanoacrylate, to the perforation site. Such a system is disclosed in U.S. Pat. No. 5,383,899.
The application of an absorbable material such as collagen or a non-absorbable tissue adhesive at the puncture site has several drawbacks including: 1) possible injection of the material into the blood vessel causing thrombosis; 2) a lack of pressure directly on the blood vessel puncture which may allow blood to escape beneath the material plug into the surrounding tissue; and 3) the inability to accurately place the absorbable material plug directly over the puncture site.
The use of an anchor and plug system addresses these problems to some extent but provides other problems including: 1) complex and difficult application; 2) partial occlusion of the blood vessel by the anchor when placed properly; and 3) complete blockage of the blood vessel or a branch of the blood vessel by the anchor if placed improperly. Another problem with the anchor and plug system involves reaccess. Reaccess of a particular blood vessel site sealed with an anchor and plug system is not possible until the anchor has been completely absorbed because the anchor could be dislodged into the blood stream by an attempt to reaccess.
Yet another approach to subcutaneous puncture closure involves the internal suturing of the blood vessel puncture with a specially designed suturing device. However, these suturing devices involve a significant number of steps to perform suturing and require substantial expertise.
The use of a bioabsorbable hemostatic foam is a promising new alternative for promoting hemostasis of a blood vessel puncture site. One example of a hemostatic foam system for facilitating hemostasis of a puncture site is described in International Publication No. WO 99/56692 which is incorporated herein by reference in its entirety. As described in this application, a pledget of compressed hemostatic foam is cut from a sheet of the foam material and is rolled into a configuration which is inserted into a delivery device. Once the foam pledget is inserted into the delivery device, the foam is hydrated, compressed, and delivered to a body for promoting hemostasis of a blood vessel puncture site.
One aspect of the present invention relates to a device for facilitating hemostasis of a puncture in the wall of a blood vessel. The device includes a delivery chamber for delivery of a sponge pledget into a patient to seal a puncture, a pusher positioned in a proximal end of the introducer for ejection of the pledget from the delivery chamber into the patient to seal the puncture, and a staging chamber removably connectable to a distal end of the delivery chamber for hydrating the sponge pledget and delivering the sponge pledget to the delivery chamber, the staging chamber having a lumen diameter which is larger than a lumen diameter of the delivery chamber.
In accordance with another aspect of the present invention, a connector for introducing fluid to a chamber includes a connector body, a releaseable coupling for coupling a first end of the connector body to the opening of the chamber, a sealing mechanism for forming a substantially fluid tight seal between the first end of the connector body and the opening of the chamber, and a lock mechanism for preventing the release of the releaseable coupling when a syringe is connected to a second end of the connector body.
In accordance with an additional aspect of the present invention, a staging system for hydrating a sponge pledget includes a staging chamber having an open lumen with a tapered section at a first end, and a connector attachable to a second end of the staging chamber for connecting a syringe to the staging chamber. The connector includes a connector body having a central lumen, a first end for connection to the staging chamber, and a second end for connection to a syringe, a releasable coupling for coupling the first end of the connector body to the staging chamber, and a sealing mechanism for forming a substantially fluid tight seal between the first end of the connector and the staging chamber.
In accordance with a further aspect of the present invention, a device for facilitating hemostasis of a puncture in the wall of a blood vessel includes a delivery cannula for delivery of a sponge pledget into a patient to seal a puncture, a pusher positioned in a proximal end of the delivery cannula for ejection of the pledget from the delivery cannula into the patient to seal the puncture, and a staging chamber having a first end removably connectable to the delivery cannula. The staging chamber has a valve with a first position for hydrating the sponge pledget and a second position for delivering the sponge pledget to the delivery cannula. The staging chamber has a lumen diameter which is larger than a lumen diameter of the delivery cannula.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
The absorbable sponge delivery systems described herein are used to deliver an absorbable sponge pledget in a hydrated condition to a blood vessel puncture site to achieve hemostasis. In general, the delivery systems include a staging chamber, a delivery cannula, and a pusher. The systems allow over the wire delivery of hydrated absorbable sponge material directly to the blood vessel puncture site to achieve hemostasis. Over the wire delivery ensures that the sponge material is properly positioned to fully occlude the puncture. In addition, the absorbable sponge material is delivered in a hydrated state which immediately expands to stop blood flow through the puncture. The staging chamber and delivery cannula allow the delivery of more absorbable sponge material through a smaller tract by hydrating and compressing the absorbable sponge material.
Prior to discussing the present invention in further detail, the following terms are defined:
“Pledget” means a piece of sponge formed into a generally elongated shape having a size which allows delivery in a hydrated state through a delivery cannula to a site of a puncture in a blood vessel.
“Sponge” means a biocompatible material which is capable of being hydrated and is resiliently compressible in a hydrated state. Preferably, the sponge is non-immunogenic and may be absorbable or non-absorbable.
“Absorbable sponge” means sponge which when implanted within a human or other mammalian body is absorbed by the body.
“Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, contrast agent, thrombin, therapeutic agents, or the like.
“Kneading” of the absorbable sponge material means both dry and wet manipulation of sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
As shown in
The easy loader connector 16 has a first end 30 for connection to the staging chamber 14 and a second end 32 including a luer fitting or other fitting for receiving a syringe or other fluid delivery member. The easy loader connector 16 also includes two snap fit tabs 34 with angled forward surfaces 36. The snap fit tabs 34 snap over the annular flange 26 on the staging chamber 14 to secure the easy loader connector 16 to the staging chamber. Each of the snap fit tabs 34 has a corresponding wing 38. The wings 38 are depressed inwardly to release the easy loader connector 16 from the staging chamber 14.
The easy loader connector 16 allows the loading opening 24 of the staging chamber 14 to be larger in diameter than the opening in a standard luer fitting which receives the syringe. The opening of a standard luer fitting is about 0.156 inches.
In use, the pledget 12 is inserted into the staging chamber 14 through the loading opening 24. The easy loader connector 16 is then attached to the staging chamber 14. A syringe 44, shown in
The easy loader connector 16 also includes a lock mechanism which prevents the connector from being disconnected from the staging chamber 14 when a syringe 44 is connected to the connector. The locking mechanism is provided by stops 40 on the wings 38. The stops 40 contact the side walls of the syringe 44 preventing the wings 38 from deflecting radially inward. This locking mechanism allows higher pressures to be used for hydration.
The pusher 52 and delivery cannula 50 are provided with interengaging lock members 62, 64 which prevent or allow relative motion of the pusher and delivery cannula in one or two axial directions depending on the relative rotational position of the lock members. The lock member 64 on delivery cannula 50 also includes two wings which may be used as a handle.
After an intervascular procedure has been completed, a guidewire 60 is already in place passing through the subcutaneous tissue 100 and into the blood vessel 102. Alternatively, if a guidewire is not already in place the guidewire is inserted through an access sheath used in the intervascular procedure and the access sheath is then removed. The guidewire 60 is maintained in place with a proximal end extending from the patients body and a distal end extending through the skin 104 and subcutaneous tissue 100, and into the blood vessel 102. A proximal end of the guidewire 60 is fed into the distal end of the delivery cannula 50 through the hydrated and compressed pledget 12 and out a proximal end of the pusher 52.
Preferably, the guidewire 60 is fed through substantially the center of the pledget 12 to ensure that the implanted pledget is substantially centered over the blood vessel puncture. Alternatively, the guidewire may be inserted along a side of the pledget 12, through a separate second lumen of the delivery cannula 50, through an axial lumen in the pledget, or through a low density center of the pledget.
The delivery cannula 50 and pusher 52 are advanced together down through the skin 104 and subcutaneous tissue 100 until the depth indicator 54 on the exterior of the delivery cannula 50 is at the skin level. If a depth indicator is not used, the proper location of the cannula 50 is determined by palpation of the vessel with the cannula, by visualization, or by other means. According to a preferred embodiment, the lock members 62, 64 are in a locked position as shown in
As shown in
The delivery system of
After hydration of the pledget, the gate valve 220 is pushed to a second position, as shown in
In addition to providing for venting and delivery of the pledget 12, the gate valve 220 can be used as a guillotine or a cutter to cut or shear off portions of the pledget 12 which extend from the distal end of the delivery cannula 50.
One type of absorbable sponge material which is acceptable for use in the present invention is Gelfoam, manufactured by the Upjohn Company. Gelfoam is a porous, pliable, cross-linked gelatin material and is available commercially in sheet form as pre-compressed or non-compressed sponge. The material may be provided preformed as a pledget 12 or may be cut with a punch, or a stencil or template and knife and rolled to form a pledget as described above. Once hydrated, the pledget 12 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of the hydrated pledget 12 during delivery encourages air trapped within the Gelfoam to be expelled and replaced with fluid, allowing rapid expansion upon delivery. When a pledget 12 of a pre-compressed Gelfoam is hydrated and kneaded (expelling air) during delivery, the pledget will have the absorption capacity to rapidly expand to many times (e.g., 3 or more times) its original dry volume upon delivery. When a pledget 12 of the non-compressed Gelfoam is hydrated and kneaded (expelling air) during delivery, the pledget will have the absorption capacity to rapidly expand to its original dry volume upon delivery. These properties make the Gelfoam sponge material particularly useful for facilitating hemostasis of puncture wounds by injection.
The absorbable sponge material can be absorbed by the body in a period of time between several days and several months depending on the absorbable sponge material used. A pledget 12 formed of commercially available Gelfoam material will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be engineered to provide different rates of absorption. For example, Gelfoam can be designed to be absorbed at different rates by varying the degree of cross-linking. Preferably, the pledget 12 is designed to be absorbed in less than one month.
Although the invention is primarily intended for delivery of absorbable sponge, non-absorbable sponge may also be delivered with the devices, systems, and methods of the present invention. A non-absorbable sponge may be desirable where it will be necessary to locate the blood vessel puncture after the procedure.
Although the pledget 12 has been described as formed from a rectangular shaped piece of an absorbable sponge material which is rolled into a cylindrical shape, the pledget may also be formed in different shapes and rolled from different shaped sheets. For example, the pledget 12 may be preformed in a variety of cross sections including circular, rectangular, star, or other multi-sided shape. The pledget 12 may have a folded cross section and may have through or blind holes formed in the dry pledget. In addition, the pledget size and shape can be matched to the size and shape of a particular delivery site.
While an amorphous or discontinuous sponge structure may be used in the present invention, a continuous structure of the delivered absorbable sponge pledget 12 provides more secure and reliable placement of a plug of material against the blood vessel puncture than a paste or liquid. The continuous sponge structure can even facilitate partial withdrawal, removal, or movement of the ejected pledget.
In accordance with one aspect of the invention, the absorbable sponge material can be hydrated with a clotting agent such as thrombin, a contrast agent, another beneficial agent, a combination of agents, or the like. Alternatively, the pledget material itself may contain an agent such as a clotting agent, a contrast agent, another beneficial agent, a combination of agents, or the like.
The treatment of a blood vessel puncture with a hydrated and injected pledget 12 of absorbable sponge to facilitate hemostasis provides substantial advantages in comfort over external pressure methods. In addition, the present invention also provides advantages over the insertion of an absorbable sponge material in a dry state or injection of a liquid or paste. In particular, the hydration and manipulation or “kneading” of the hydrated Gelfoam pledget 12 as it is passed through the staging chamber improves the expansion and absorption characteristics of the Gelfoam. The injected Gelfoam conforms in shape quickly to the shape of the puncture site and immediately begins blocking blood flow through the puncture site and providing local compression. In contrast, a dry piece of sponge material does not swell until the blood has sufficiently saturated the sponge material, which can take up to hours. The hydrated and kneaded sponge material will expand to a larger size much more quickly when wetted than a piece of dry sponge material when wetted.
Because the amount of subcutaneous fat and tissue between the skin and the blood vessel varies between patients from approximately 0.5 cm to 15 cm or more the system may be provided in different lengths for use in different patients. The pledget 12 size and shape may also be varied for different patients. The absorbable sponge material should form a complete plug over the puncture site without expanding into the blood vessel or exiting the skin of the patient. In some instances where the amount of subcutaneous tissue is great it may be desirable to deliver multiple pledgets 12 in spaced apart positions along the tract leading to the puncture site. The particular size and shape of the delivery system may vary depending on the size of the access site, amount of subcutaneous tissue, and the size of pledget 12 to be delivered. While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a continuation of U.S. patent application Ser. No. 09/570,857, entitled “System and Method for Facilitating Hemostasis of Blood Vessel Punctures with Absorbable Sponge” by inventors Mark Ashby, Luis R. Urquidi and Eric Lee, filed on May 12, 2000 now U.S. Pat. No. 6,540,735.
Number | Name | Date | Kind |
---|---|---|---|
581235 | Kenyon | Apr 1897 | A |
1578517 | Hein | Mar 1926 | A |
2086580 | Shirley | Jul 1937 | A |
2370319 | Lippincott | Feb 1945 | A |
2465357 | Correll | Mar 1949 | A |
2492458 | Bering, Jr. | Dec 1949 | A |
2507244 | Correll | May 1950 | A |
2558395 | Studer | Jun 1951 | A |
2597011 | MacMasters, et al. | May 1952 | A |
2680442 | Linzmayer | Jun 1954 | A |
2761446 | Reed | Sep 1956 | A |
2814294 | Figge | Nov 1957 | A |
2824092 | Thompson | Feb 1958 | A |
2874776 | Hooe | Feb 1959 | A |
2899362 | Sieger, Jr. et al. | Aug 1959 | A |
3157524 | Artandi | Nov 1964 | A |
3358689 | Higgins | Dec 1967 | A |
3411505 | Nobis | Nov 1968 | A |
3724465 | Duchane | Apr 1973 | A |
3736939 | Taylor | Jun 1973 | A |
4000741 | Binard et al. | Jan 1977 | A |
4098728 | Rosenblatt | Jul 1978 | A |
4211323 | Olsen | Jul 1980 | A |
4218155 | Weidner | Aug 1980 | A |
4219026 | Layton | Aug 1980 | A |
4224945 | Cohen | Sep 1980 | A |
4238480 | Sawyer | Dec 1980 | A |
4292972 | Pawelchak | Oct 1981 | A |
4323072 | Rosenbluth et al. | Apr 1982 | A |
4340066 | Shah | Jul 1982 | A |
4390018 | Zulowski | Jun 1983 | A |
4404970 | Sawyer | Sep 1983 | A |
4405314 | Copi | Sep 1983 | A |
4515637 | Cioca | May 1985 | A |
4573576 | Krol | Mar 1986 | A |
4587969 | Gillis | May 1986 | A |
4588395 | Lemelson | May 1986 | A |
4619261 | Guerriero | Oct 1986 | A |
4619913 | Luck et al. | Oct 1986 | A |
4644649 | Seaman et al. | Feb 1987 | A |
4645488 | Matukas | Feb 1987 | A |
4699616 | Norwak et al. | Oct 1987 | A |
4708718 | Daniels | Nov 1987 | A |
4744364 | Kensey | May 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4829994 | Kurth | May 1989 | A |
4832688 | Sagae et al. | May 1989 | A |
4839204 | Yoshino | Jun 1989 | A |
4850960 | Grayzel | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4869143 | Merrick | Sep 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4936835 | Haaga | Jun 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
5007895 | Burnett | Apr 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5049138 | Chevalier et al. | Sep 1991 | A |
5053046 | Janese | Oct 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5080655 | Haaga | Jan 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5129889 | Hahn et al. | Jul 1992 | A |
5163904 | Lampropoulos et al. | Nov 1992 | A |
5167624 | Butler et al. | Dec 1992 | A |
5192290 | Hilgal | Mar 1993 | A |
5192300 | Fowler | Mar 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5195988 | Haaga | Mar 1993 | A |
5219899 | Panster et al. | Jun 1993 | A |
5220926 | Jones | Jun 1993 | A |
5221259 | Weldon et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5242683 | Klaveness | Sep 1993 | A |
5254105 | Haaga | Oct 1993 | A |
5275616 | Fowler | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5310407 | Casale | May 1994 | A |
5320639 | Rudnick | Jun 1994 | A |
5322515 | Karas et al. | Jun 1994 | A |
5325857 | Nabai et al. | Jul 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5342388 | Toller | Aug 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5352211 | Merskelly | Oct 1994 | A |
5366480 | Corriveau et al. | Nov 1994 | A |
5370656 | Shevel | Dec 1994 | A |
5383896 | Gershony et al. | Jan 1995 | A |
5383899 | Hammerslag | Jan 1995 | A |
5385550 | Su et al. | Jan 1995 | A |
5388588 | Nabai et al. | Feb 1995 | A |
5391183 | Janze et al. | Feb 1995 | A |
5399361 | Song et al. | Mar 1995 | A |
5417699 | Klein | May 1995 | A |
5419765 | Weldon et al. | May 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5437292 | Kipshidze | Aug 1995 | A |
5437631 | Janzen | Aug 1995 | A |
5443481 | Lee | Aug 1995 | A |
5447502 | Haaga | Sep 1995 | A |
5458570 | May, Jr. | Oct 1995 | A |
5467780 | Nabai et al. | Nov 1995 | A |
5478352 | Folwer | Dec 1995 | A |
5479936 | Nabai et al. | Jan 1996 | A |
5486195 | Myers et al. | Jan 1996 | A |
5490736 | Haber | Feb 1996 | A |
5507279 | Fortune | Apr 1996 | A |
5522840 | Krajicek | Jun 1996 | A |
5522850 | Yomtov et al. | Jun 1996 | A |
5526822 | Burbank et al. | Jun 1996 | A |
5527332 | Clement | Jun 1996 | A |
5529577 | Hammerslag | Jun 1996 | A |
5540715 | Katsaros et al. | Jul 1996 | A |
5542914 | Van Iten | Aug 1996 | A |
5545175 | Abidin et al. | Aug 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5558853 | Quay | Sep 1996 | A |
5571168 | Toro | Nov 1996 | A |
5591204 | Janzen et al. | Jan 1997 | A |
5591205 | Fowler | Jan 1997 | A |
5601601 | Tal et al. | Feb 1997 | A |
5601602 | Fowler | Feb 1997 | A |
5601603 | Illi | Feb 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5645566 | Brenneman et al. | Jul 1997 | A |
5649547 | Ritchart et al. | Jul 1997 | A |
5653730 | Hammerslag | Aug 1997 | A |
5665107 | Hammerslag | Sep 1997 | A |
5674346 | Kundel | Oct 1997 | A |
5676689 | Kensey et al. | Oct 1997 | A |
5681279 | Roper et al. | Oct 1997 | A |
5707393 | Kensey et al. | Jan 1998 | A |
5716375 | Fowler | Feb 1998 | A |
5725498 | Janzen et al. | Mar 1998 | A |
5741223 | Janzen et al. | Apr 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5775333 | Burbank et al. | Jul 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5810806 | Ritchart et al. | Sep 1998 | A |
5830130 | Janzen et al. | Nov 1998 | A |
5858008 | Capaccio | Jan 1999 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5931165 | Reich et al. | Aug 1999 | A |
5948425 | Janzen et al. | Sep 1999 | A |
5964785 | Desecki et al. | Oct 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6027471 | Fallon et al. | Feb 2000 | A |
6027482 | Imbert | Feb 2000 | A |
6033427 | Lee | Mar 2000 | A |
6045569 | Kensey et al. | Apr 2000 | A |
6048357 | Kontos | Apr 2000 | A |
6056768 | Cates et al. | May 2000 | A |
6066325 | Wallace et al. | May 2000 | A |
6071300 | Brenneman et al. | Jun 2000 | A |
6071301 | Cragg et al. | Jun 2000 | A |
6086607 | Cragg et al. | Jul 2000 | A |
6090130 | Nash et al. | Jul 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6161034 | Burbank et al. | Dec 2000 | A |
6162192 | Cragg et al. | Dec 2000 | A |
6183497 | Sing et al. | Feb 2001 | B1 |
6200328 | Cragg et al. | Mar 2001 | B1 |
6315753 | Cragg et al. | Nov 2001 | B1 |
6325789 | Janzen et al. | Dec 2001 | B1 |
6350274 | Li | Feb 2002 | B1 |
6371974 | Brenneman et al. | Apr 2002 | B1 |
6440151 | Cragg et al. | Aug 2002 | B1 |
6440153 | Cragg et al. | Aug 2002 | B2 |
6447534 | Cragg et al. | Sep 2002 | B2 |
6527734 | Cragg et al. | Mar 2003 | B2 |
6540735 | Ashby et al. | Apr 2003 | B1 |
6544236 | Cragg et al. | Apr 2003 | B1 |
6610026 | Cragg et al. | Aug 2003 | B2 |
20020042378 | Reich et al. | Apr 2002 | A1 |
20030088271 | Cragg et al. | May 2003 | A1 |
Number | Date | Country |
---|---|---|
32826 | Jul 1981 | EP |
476178 | Mar 1992 | EP |
482350 | Apr 1992 | EP |
0557963 | Feb 1993 | EP |
0637431 | Nov 1994 | EP |
2 641 692 | Jul 1990 | FR |
1509023 | Apr 1978 | GB |
1569660 | Jun 1980 | GB |
782814 | Nov 1980 | RU |
1088709 | Apr 1984 | RU |
WO 9112847 | Sep 1991 | WO |
WO 9402072 | Feb 1994 | WO |
WO 9428800 | Dec 1994 | WO |
WO 9528124 | Oct 1995 | WO |
WO 9532669 | Dec 1995 | WO |
WO 9532671 | Dec 1995 | WO |
WO 9532679 | Dec 1995 | WO |
WO9608208 | Mar 1996 | WO |
WO 9624290 | Aug 1996 | WO |
WO 9709934 | Mar 1997 | WO |
WO9086346 | Feb 1998 | WO |
WO 9966834 | Dec 1999 | WO |
Number | Date | Country | |
---|---|---|---|
20030120258 A1 | Jun 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09570857 | May 2000 | US |
Child | 10366752 | US |